ADHD, Arrhythmias, Cardiac, Cardiovascular Abnormalities, Cardiovascular Diseases, Congenital Abnormalities, Death, Death, Sudden, Death, Sudden, Cardiac, Depression, Electrocardiogram: Electrical Alternans, Genetic Disease, Genetic Syndrome, Heart Arrest, Heart Defects, Congenital, Heart Diseases, Long QT Syndrome, Pathologic Processes, Psychiatric Disorder, Qt Interval, Variation in, Romano-Ward Syndrome
Conditions
Brief summary
Studies have shown that the risk of developing heart arrhythmias, is increased in patients receiving medication for Attention-deficit hyperactivity disorder (ADHD) and depression. The QT-interval on a electrocardiogram (ECG) is often used to assess the patients risk of developing heart arrhythmias. The QT-interval defines the hearts electrical resting period and a long interval is linked to an increased risk of developing heart arrhythmias. In this project the investigators wish to examine possible side-effects in patients receiving medication for ADHD and depression and their dynamic QT-interval changes, by analysing the ECG changes that occur during Brisk Standing.
Interventions
DIAGNOSTIC_TESTElectrocardiogram examination
12-lead ECG monitored by Holter
DIAGNOSTIC_TESTEchocardiography
Echocardiography in accordance to Danish Society of Cardiology
PROCEDUREBlood Samples
Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
BEHAVIORALQuestionnaire
Questionnaire regarding patients quality of life
Sponsors
Copenhagen University Hospital at Herlev
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Over 18 years old * Patients treated with Methylphenidate * Patients treated with Methylphenidate and QT-prolonging SSRI * Patients treated with Methylphenidate and a non QT-prolonging SSRI
Exclusion criteria
* Patients considered in an unstable phase in their psychiatric condition * Patients that are not able to understand the information regarding the trial, or who are unable to cooperate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ECG changes | Through study completion, an average of 1 year. | The Primary Outcome assess whether there are changes on ECG, primary the QTc-interval, in participants receiving medication for ADHD and depression. |
Countries
Denmark
Outcome results
None listed